|
DAY 1: Monday, February 07, 2011
|
|
3rd International Conference on
Drug Discovery & Therapy
February 7– 10, 2011, Dubai Women’s College, Dubai,
UAE
www.icddt.com
|
|
TIME
|
INAUGURAL PROGRAM
|
|
09:00
-10.00 a.m.
|
Welcome Reception
|
Arrival of Participants and Guests
|
|
10.00
a.m.
|
Opening Ceremony
|
|
|
National Anthem
|
|
Opening Address
|
His Excellency Sheikh Nahayan Mabarak Al Nahayan
Minister of Higher Education and Scientific Research
Chancellor, Higher Colleges of Technology
Patron of the 3rd ICDDT
|
|
Keynote Addresses
|
Prof. Dr. Ferid Murad, (Nobel Laureate),
Co-President, 3rd ICDDT
Prof. Dr. Atta-ur-Rahman, FRS,
Co-President, 3rd ICDDT
|
|
11:00
a.m.
|
Coffee Break
|
|
|
COFFEE BREAK: 11:00 – 11:45 a.m.
|
|
PLENARY SESSION
|
|
Time
|
Chairman: F. Murad
Co-Chairman: G. Mehta
|
Speaker
|
Title
|
|
11:45
12:30 p.m.
|
Location:
Auditorium
|
R. Huber (Nobel Laureate)
PL-1
|
Structure-based drug design & development with
the proteasome & other intra-cellular proteases
|
|
12:30
01:15 p.m.
|
Location:
Auditorium
|
E. Neher (Nobel Laureate)
PL-2
|
Signals and
signaling molecules in the central nervous system
|
|
01:15
02:00 p.m.
|
Location:
Auditorium
|
W. Arber (Nobel Laureate)
PL-3
|
Molecular mechanisms
of genetic variation, the driving force of biological evolution
|
|
LUNCH BREAK: 2:00 – 3:15 p.m.
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
|
|
Drug Delivery & Targeting/
In-Silico Drug
Design & In-Silico Screening
|
CNS Drug Discovery & Therapy
|
Regenerative Medicine/Structural Biology
|
Hot Topics in Medicinal Chemistry
|
Diabetes & Obesity Drug Discovery
& Therapy/Enabling
Technologies
|
|
|
Chairman: J. Spencer
Co-Chairman: T. Bocan
|
Chairman: I. Greiner
Co-Chairman: D.P. Ramji
|
Chairman: H. Chao
Co-Chairman: Y.J. Woo
|
Chairman: I.M. Shah
Co-Chairman: V. da Silva Bolzani
|
Chairman: D.K. Lahiri
Co-Chairman: T.L. Peeters
|
|
03:15
03:45
p.m.
|
A.C. Tedesco
IL-4
Phthalocyanines derivatives loaded on liquid-crystal
nanodispersions gel to skin cancer fluorescence diagnosis
|
03:15
03:45
p.m.
|
B.A. Tannous
IL-5
A novel in-vitro and in-vivo functional drug
screening assay reveals lanatoside C as a potential therapeutic for
glioblastoma
|
03:15
03:45
p.m.
|
M. Korbling
IL-6
Sex-mismatched stem cell transplantation: a clinical
model for solid-organ tissue regeneration
|
03:15
03:45
p.m.
|
T. Yamasaki
IL-7
D-Psicose inhibits the growth of L1 stage Caenorhabditis
elegans: a possible inhibition mechanism
|
03:15
03:45
p.m.
|
N.A. Khan
IL-8
A taste for fat: cell signaling mechanisms in the tongue
papillae
|
|
03:45
04:15
p.m.
|
A. Coombes
IL-9
Elucidating the protein release behavior of matrix-type
delivery devices using Micro-CT
|
03:45
04:15
p.m.
|
N.S. Zefirov
IL-10
Molecular design of neuroprotectors and cognition enhancers:
from theory to drugs
|
03:45
04:15
p.m.
|
N. Benkirane-Jessel
IL-11
Nanostructured active biomaterials for tissue
engineering applications
|
03:45
04:15
p.m.
|
P.B. Binello
IL-12
Precancerous lesions of the oral cavity: Prevention,
diagnosis and cure: The state of the art
|
03:45
04:15
p.m.
|
T. Orban
IL-13
Autoantigen specific regulatory T cells induced in
patients with type 1 Diabetes Mellitus
|
|
04:15
04:35
p.m.
|
S. Guo
SL-14
Drug-loaded multilayered films featuring
uni-/dual-directional, highly adjustable, long-term sustained drug release
behaviors for single-/dual-drug delivery stent application to treat malignant
bodily tubular structures or cavities
|
04:15
04:45
p.m.
|
J. Gallinat
IL-15
In vivo cerebral glutamate monitoring in schizophrenia: Glutamate normalization
in response to NMDA-receptor antagonist
|
04:15
04:35
p.m.
|
M. Bahr
SL-16
New gene therapy approaches for treatment of Parkinson’s
disease
|
04:15
04:45
p.m.
|
T.H. Al-Tel
IL-17
Diversity oriented synthesis: synthesis, design and
qualitative SAR analysis of novel anticancer motifs
|
04:15
04:35
p.m.
|
D.S.P. Abdalla
SL-18
Anti-inflammatory and antioxidant effects of a new
arylidene-thiazolidinedione on macrophages
|
|
04:35
04:55
p.m.
|
A. Bouakaz
SL-19
Local drug delivery with ultrasound and microbubbles
|
04:45
05:05
p.m.
|
J. Feldon
SL-20
Prenatal infections and long-term mental outcome: Modeling
schizophrenia-related dysfunctions using the prenatal polyl: C model in mice
|
04:35
04:55
p.m.
|
L. Calza
SL-21
Stem cells for CNS repair: alternatives to the unlikely
mechanism of cell replacement
|
04:45
05:05
p.m.
|
F.B.H. Ahmad
SL-22
Enzymatic synthesis of some betulinic acid derivative:
enhance their bioactivity
|
04:35
04:55
p.m.
|
J. Singh
SL-23
Cationic nanoparticles / nanomicelles for delivery of
pDNA encoding IL-10 and pDNA encoding IL-4 and IL-10 to prevent autoimmune Diabetes
|
|
04:55
05:15
p.m.
|
V.B. Sulimov
SL-24
Molecular modeling in drug design: Technology and
successful examples
|
05:05
05:25
p.m.
|
A.A. El-Rahim Abdin
SL-25
Intervention of mitochondrial dysfunction-oxidative
stress-dependent apoptosis as a possible neuroprotective mechanism of
alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity
|
04:55
05:25
p.m.
|
IL-26
|
05:05
05:25
p.m.
|
H. Fallahzadeh
SL-27
HIV/AIDS Epidemic features and trends in Iran, 1986-2010
|
04:55
05:15
p.m.
|
F.Q. Parray
SL-28
Colonic J Pouch Neorectum-Is it a real gold standard?
|
|
Conference Social Mixer: 5:15 – 6:15 p.m.
The buses will leave for hotels at 6:15 p.m.
|
|
DAY 2: Tuesday, February 08, 2011
|
|
PLENARY SESSION
|
|
Time
|
Chairman: R. Huber
Co-Chairman: A.R. Fersht
|
Speaker
|
Title
|
|
09:00
09:45
a.m.
|
Location: Auditorium
|
F. Murad (Nobel Laureate)
PL-29
|
Application of nitric oxide research to drug
development and disease therapy
|
|
09:45
10:30
a.m.
|
Location: Auditorium
|
J.-M. Lehn (Nobel Laureate)
PL-30
|
From supramolecular towards adaptive chemistry drug
discovery aspects
|
|
COFFEE BREAK: 10:30 – 11:15 a.m.
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
|
|
Drug Delivery & Targeting/
Anti-Cancer Drug Discovery & Therapy
|
CNS Drug Discovery & Therapy
|
Cardiovascular Drug Discovery & Therapy
|
Enabling Technologies/Hot Topics in HIV Research
|
Recent Advances in Patient Treatment & Care
|
|
|
Chairman: N.A. Darmani
Co-Chairman: P. Srinivas
|
Chairman: B.A. Tannous
Co-Chairman: N. Zefirov
|
Chairman: M.F.A. Adamo
Co-Chairman: N. Benkirane-Jessel
|
Chairman: T. Yamasaki
Co-Chairman: P. Nemani
|
Chairman: J.G. Zayas
Co-Chairman: E. Terpos
|
|
11:15
11:45
a.m.
|
Y. Tamaki
IL-31
Novel nanotechnology-based drug delivery in photodynamic
therapy for age-related macular degeneration
|
11:15
11:45
a.m.
|
I. Greiner
IL-32
Cariprazine, an antipsychotic PIII compound
|
11:15
11:45
a.m.
|
D.P. Ramji
IL-33
The macrophage foam cell as a promising therapeutic
target for atherosclerosis
|
11:15
11:45
a.m.
|
P. Stadler
IL-34
Robot-assisted Vascular Surgery
|
11:15
11:45
a.m.
|
R.-P. Mueller
IL-35
The successful coordination of chemo- and radiotherapy
to optimize outcome and toxicity in early stages Hodgkin’s Lymphoma. The
final results of the HD-10 trial of the German Hodgkin study group with 1370
patients
|
|
11:45
12:15
p.m.
|
IL-36
|
11:45
12:15
p.m.
|
W. Jia
IL-37
Innovative approaches for a novel antidepressant from
traditional Chinese medicine
|
11:45
12:15
p.m.
|
Y.J. Woo
IL-38
Mathematically designed synthetic polypeptide analog of
stromal cell-derived factor 1 alpha functions as a superpotent
neovasculogenic agent for treating myocardial ischemia
|
11:45
12:15
p.m.
|
S. Stahl
IL-39
Affibody technology targeting cancer and Alzheimer’s
disease
|
11:45
12:15
p.m.
|
R.L. Jones
IL-40
Advances in the systemic management of sarcomas
|
|
12:15
12:45
p.m.
|
B. Fang
IL-41
Developing novel multipathway modulating anticancer
agents
|
12:15
12:45
p.m.
|
S. Bellino
IL-42
Recent advances in treatment of borderline personality
disorder (BPD)
|
12:15
12:45
p.m.
|
H. Tomoda
IL-43
In-vivo efficacy of pyripyropene derivatives in atherogenic mouse
models
|
12:15
12:45
p.m.
|
M. Koffas
IL-44
Engineering plant secondary metabolite biosynthesis in
microorganisms
|
12:15
12:45
p.m.
|
T.L. Peeters
IL-45
How to let patients benefit of motilides: A new approach
|
|
12:45
01:15
p.m.
|
S.A. Grando
IL-46
Anti-Tumorigenic effects of small cholinergic peptides
of the LY6 protein family
|
12:45
01:15
p.m.
|
Y. Tanaka
IL-47
Aphasia, anxiety, and beta-adrenergic antagonists
|
12:45
01:15
p.m.
|
F.A. Villamena
IL-48
Development of new spin traps for therapeutics
|
12:45
01:15
p.m.
|
R. Di Santo
IL-49
Diketo acids derivatives as dual inhibitors of human
immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H
Domain
|
12:45
01:15
p.m.
|
A. Di Pietro
IL-50
Targeting the multidrug resistance-conferring ABC
transporters overexpressed in cancer cells: in-vitro optimization and in-vivo
validation
|
|
01:15
01:45
p.m.
|
IL-51
|
01:15
01:45
p.m.
|
Y. Iwasaki
IL-52
Trophic effect of olmesartan on spinal motor neurons in
vitro and in vivo
|
01:15
01:45
p.m.
|
A.J. Merched
IL-53
Vascular inflammation: Light at the end of the tunnel
|
01:15
01:45
p.m.
|
M. Peterlin
IL-54
HIV latency and HDAC inhibitors
|
01:15
01:35
p.m.
|
C.S. Ulrik
SL-55
Management of Asthma in pregnancy
|
|
LUNCH BREAK: 01:45 – 02:45 p.m.
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
|
|
Anti-Cancer Drug Discovery & Therapy/Stereoselective Synthesis of Bioactive Compounds
|
Medical Imaging
|
Inflammation & Immunology
|
Hot Topics in Natural Products
|
Diabetes & Obesity Drug Discovery & Therapy/
High-Throughput
Screening & Laboratory Automation
|
|
|
Chairman: B. Fang
Co-Chairman: A. Albini
|
Chairman: S. Bellino
Co-Chairman: Y. Tanaka
|
Chairman: P.C. Heinrich
Co-Chairman: F.A. Villamena
|
Chairman: P.B. Binello
Co-Chairman: O. Hammarsten
|
Chairman: N.A. Khan
Co-Chairman: D.S.P. Abdalla
|
|
02:45
03:15
p.m.
|
U. Manne
IL-56
Effect of pre-clinical research on cancer disparities to
evidence-based care
|
02:45
03:05
p.m.
|
A. Benabarre
SL-57
The correlation of cerebral blood flow and neuropsychology
in bipolar patients
|
02:45
03:05
p.m.
|
S.Y. Seong
SL-58
Agonist for G-protein coupled receptor 131 attenuate
systemic inflammatory syndrome
|
02:45
03:05
p.m.
|
R.D. Lele
SL-59
Chemoprevention of cancer
|
02:45
03:05
p.m.
|
M.A. Leissring
SL-60
Designed inhibitors of insulin-degrading enzyme as
promising pharmacophores for the treatment of diabetes
|
|
03:15
03:35
p.m.
|
P. Srinivas
SL-61
Multifaceted approach with a single drug for BRCA1
defective cancers
|
03:05
03:25
p.m.
|
F. Pilleul
SL-62
CT scan in colonic cancer as a screening test
|
03:05
03:25
p.m.
|
A.I. Tchorbanov
SL-63
Experimental therapy in humanized SCID mice models of
SLE
|
03:05
03:25
p.m.
|
D. de F. Buchi
SL-64
M1 as a promising product that modulates NF-kB activation
|
03:05
03:25
p.m.
|
D. Li
SL-65
Fibroblast growth factor-21 ameliorates both diabetes
and obesity
|
|
03:35
03:55
p.m.
|
S. Gou
SL-66
Biological evaluation of novel structure-activity
platinum complexes
|
03:25
03:45
p.m.
|
Y. Ni
SL-67
Medical imaging research leads to discovery of a new
anticancer strategy
|
03:25
03:45
p.m.
|
J. Vojinovic
SL-68
First use of oral histone deacetylase inhibitor
(Givinostat) in systemic Onset Juvenile Idiopathic Arthristic (Sojia)
|
03:25
03:45
p.m.
|
E.V. Soniya
SL-69
A novel polyketide synthase from ginger – a prime
candidate for natural medicinal compound biosynthesis
|
03:25
03:45
p.m.
|
F. Samad
SL-70
Targeting de novo ceramide biosynthesis
ameliorates multiple features of the metabolic syndrome in diet induced
obesity
|
|
03:55
04:15
p.m.
|
N.A. Darmani
SL-71
A re-evaluation of the neurochemical and anatomical
bases of chemotherapy-induced vomiting
|
03:45
04:05
p.m.
|
M. Chorazy
SL-72
Histopathological diagnosis of small cell lung cancer
through the biopsy of spleen metastases under ultrasound examination
|
03:45
04:05
p.m.
|
J.N. Agrewala
SL-73
Caerulomycin A: A novel immunosuppressive agent that
modulates the activity of both T cells and B cells
|
03:45
04:05
p.m.
|
M.A. O’Neil-Johnson
SL-74
High-throughput natural products chemistry for drug
discovery: Is it possible?
|
03:45
04:15
p.m.
|
J.G. Bueno
IL-75
Antimicrobial drug discovery, screening predicts the
clinical outcome?
|
|
04:15
04:35
p.m.
|
J.K. Ray
SL-76
Use of “halo vinyl aldehydes” in organic synthesis and chemo selective
functional group transformations in gamma lactam derivatives
|
04:05
04:25
p.m.
|
W.A. Zaghary
SL-77
Labeling and biodistribution of 99mTc-7-Bromo-1,
4-dihydro-4-oxo-quinolin-3-carboxylic acid complex
|
04:05
04:25
p.m.
|
L.Y. Al-Ayadhi
SL-78
Serum levels of brain-derived neurotrophic factor (BDNF)
in autistic children
|
04:05
04:25
p.m.
|
P.M. Sherief
SL-79
Extraction, characterization, antioxidant property and
anti-inflammatory activity of carotenoids from the shell waste of Arabian red
shrimp Aristeus alcocki (Ramadan, 1938)
|
04:15
04:35
p.m.
|
Y.-T. Chang
SL-80
Development of bioimaging probes for in-vitro, in-vivo
and clinical applications by diversity oriented fluorescence library approach
(DOFLA)
|
|
POSTER PRESENTATION: 04:25 – 6:00 p.m.
|
|
Posters Session: 4:25 – 6:00 p.m. at corridor
Gala Dinner at Dhow Cruise: Departure at
6:00 p.m.
The buses will leave for hotels at 8:30
p.m.
|
|
DAY 3:
Wednesday, February 09, 2011
|
|
PLENARY SESSION
|
|
Time
|
Chairman: E. Neher
Co-Chairman: T. Bocan
|
Speaker
|
Title
|
|
09:00
09:45
a.m.
|
Location: Auditorium
|
G. Mehta
PL-81
|
Probing synergy between natural products and total
synthesis for human wellbeing
|
|
09:45
10:30
a.m.
|
Location: Auditorium
|
Sir A.R. Fersht
PL-82
|
The tumour suppressor p53: From structure to drug
discovery
|
|
COFFEE BREAK: 10:30 – 11:15 a.m.
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
Hall No. HS-1008
(Ground Floor)
|
|
|
Hot Topics in Drug Targets
|
Drug Discovery in Preclinical Research
|
Proteomics & Bioinformatics/
Pharmaceutical
Research & Development
|
Pharmacogenomics/
Translational
Medicine
|
Hot Topics in Natural Products/Recent Advances in Patient Treatment & Care
|
Academic CRO/Industrial
Collaborations in Drug Discovery
|
|
|
Chairman: B. Stefanovic Co-Chairman: J. Vojinovic
|
Chairman: Taleb Al-Tel
Co-Chairman: M.A. Leissring
|
Chairman: G.H. Scherr
Co-Chairman: Prathima Srinivas
|
Chairman: S.Y. Seong
Co-Chairman: N. Benkirane-Jessel
|
Chairman: I. Toth
Co-Chairman: A. Kocak
|
Chairman: A. Al Amiri
Co-Chairmen: M. Al-Farhan /K. Kodukula
|
|
11:15
11:45
a.m.
|
P. Nemani
IL-83
Targeting gp96 to prevent neonatal meningitis
|
11:15
11:45
a.m.
|
M.I. Choudhary
IL-84
Productivity crises in pharmaceutical sector – Nature’s
Answer
|
11:15
11:45
a.m.
|
I.H. Khan
IL-85
Phosphoproteomic profiling of signaling pathways in
cancer cells by microparticle suspension arrays
|
11:15
11:45
a.m.
|
I.M. Shah
IL-86
Antithrombotic therapy and cytochrome P450 pharmacogenomics
|
11:15
11:45
a.m.
|
O. Hammarsten
IL-87
Repeated transient sulforaphane stimulation in
astrocytes leads to prolonged Nrf2-mediated gene expression and protection
from superoxide-induced damage
|
11:15
12:15
p.m.
|
R. Chaguturu
SIL-88
Current trends in collaborative drug discovery and
strategies to De-risk open innovation-based precompetitive initiatives
|
|
11:45
12:15
p.m.
|
G. Sansoe
IL-89
Portal hypotensive action of calcimimetic agents in rats
with Ccl4-induced ascitic liver cirrhosis
|
11:45
12:15
p.m.
|
D.K. Lahiri
IL-90
Discovery of a novel drug target for Alzheimer’s
disease: miR-101 regulates levels of the amyloid precursor protein
|
11:45
12:05
p.m.
|
R. Issa
SL-91
Identification of glucosinolate QTLs in Brassica
oleracca C genome revealed interesting genome regions for biological
applications
|
11:45
12:05
p.m.
|
A. Lezhava
SL-92
Rapid detection of clinically important SNPs and mutations
by two-color SmartAmp method
|
11:45
12:15
p.m.
|
V. da Silva Bolzani
IL-93
Will natural chemistry diversity from tropical
biodiversity continue to inspire medicinal chemistry?
|
|
12:15
12:45
p.m.
|
L. Lafanechere
IL-94
A new pharmacological inhibitor of LIM Kinase that
blocks cell motility and stabilizes microtubules
|
12:15
12:45
p.m.
|
M.D. Hamalainen
IL-95
The importance of drug-target binding kinetics for drug
efficacy – Without on you are off!
|
12:05
12:25
p.m.
|
T. Shah
SL-96
The use of proteomics and bioinformatics to develop a
serum based diagnostic test for feline lymphoma
|
12:05
12:35
p.m.
|
C.J. Henry
IL-97
Use of spontaneously arising canine TCC as a relevant
model of late-stage human bladder cancer in which to assess the novel drug,
Tavocept TM, for its ability to mitigate toxicity and improve
efficacy of a cisplatin and piroxicam combination therapy protocol
|
12:15
12:45
p.m.
|
M.-T. Liong
IL-98
Cholesterol-reducing effects of a symbiotic containing Lactobacillus
acidophilus and inulin in hypercolesterolemic subjects
|
12:15
12:45
p.m.
|
W.R. Hume
IL-99
Productive government, university and industry
relationships in research
|
|
12:45
01:05
p.m.
|
N.V. Koshkina
SL-100
The Fas mechanism as a novel target to treat lung
metastases using metastatic osteosarcoma model
|
12:45
01:05
p.m.
|
F. Vyskocil
SL-101
Alkylammonium derivatives of 6-methyluracil act as
tissue-specific inhibitors of acetylcholine esterases in muscle and brain
|
12:25
12:45
p.m.
|
T. Comoglu
SL-102
Formulation technologies & future research trends of
orally fast disintegrating Tablets
|
12:35
01:05
p.m.
|
P. Bernardi
IL-103
Toward a mitochondrial therapy of muscular dystrophies:
From mouse model to clinical trial
|
12:45
01:15
p.m.
|
J. Schripsema
IL-104
Metabolomics in the discovery of novel drugs
|
12:45
01:05
p.m.
|
N. Sulaiman
SL-105
Academia-industry collaboration in training and research
– the Sharjah model
|
|
01:05
01:25
p.m.
|
P. Trapencieris
SL-106
New selective CA-I inhibitors
|
01:05
01:25
p.m.
|
R.J. Anto
SL-107
Chemosensitizing efficacy of curcumin in paclitaxel
chemotherapy as evidenced by chemical-induced and xenograft models of
cervical cancer
|
12:45
01:05
p.m.
|
G. Shahnaz
SL-108
Intestinal lymphatic drug delivery of phenothiazines by ex-vivo
model: Influence of self-nanoemulsifying formulation design
|
01:05
01:25
p.m.
|
V.N. Smirnov
SL-109
Cord blood cells (CBC) in the treatment of brain trauma
and cerebral palsy
|
01:15
01:35
p.m.
|
E. Terpos
SL-110
The role of antiresorptive agents in the management of
multiple myeloma-related bone disease
|
01:05
01:25
p.m.
|
O. Shafey
SL-111
Regulation and promotion of health research in Abu Dhabi
|
|
01:05
01:25
p.m.
|
S. Danti
SL-112
Middle Ear Tissue Engineering: new challenges and
opportunities for otologic surgery
|
|
LUNCH BREAK: 01:25 – 2:30 p.m.
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
Hall No. HS-1008
(Ground Floor)
|
|
|
Inflammation & Immunology/Hot Topics in Drug Targets/Innovative Drug Discovery &
Nanotechnology
|
Recent Advances in Spectroscopy/ Proteomics & Bioinformatics
|
Anti-Infectives/Hot Topics in Medicinal Chemistry
|
Hot Topics in Natural Products
|
Recent Advances in Patient Treatment & Care
|
Academic CRO/Industrial
Collaborations in Drug Discovery
|
|
|
Chairman: L. Lafanechere
Co-Chairman: G. Sansoe
|
Chairman: I.H. Khan
Co-Chairman: D.K. Lahiri
|
Chairman: F. Pilleul
Co-Chairman: Y. Ni
|
Chairman: M.T. Liong
Co-Chairman: R.D. Lele
|
Chairman: R.L. Jones
Co-Chairman: H. Chao
|
Chairman: R. Chaguturu
Co-Chairman: K. Kodukula
|
|
02:30
03:00
p.m.
|
P.C. Heinrich
IL-113
Pro-inflammatory cytokines impair IL-6 mediated STAT3
activation by serine phosphorylation and subsequent internalization of the
signal transducer gp130
|
02:30
03:00
p.m.
|
A. Kocak
IL-114
The role of vibrational spectroscopy in modern forensic science
research
|
02:30
03:00
p.m.
|
G.H. Scherr
IL-115
Instant hand sanitizers
|
02:30
03:00
p.m.
|
M.A. O’Neil-Johnson
IL-116
New chemical scaffold starting points for targeting
inflammation preferred, novel and neglected scaffolds in a drug discovery
program
|
02:30
03:00
p.m.
|
D. Martin
IL-117
Intraoperative radiation therapy: Past, present &
future
|
02:30
03:00
p.m.
|
S. Herzig
IL-118
Graduate program in pharmacology and experimental
therapeutics – a joint endeavor of the University of Cologne and Bayer
Schering
|
|
03:00
03:30
p.m.
|
A.M. Artoli
IL-119
Mechanism of inflammation: A simulation approach
|
03:00
03:20
p.m.
|
A. Freiberg
SL-120
Membrane proteins under high hydrostatic pressure reveal cooperative
and reversible rupture of hydrogen bonds
|
03:00
03:20
p.m.
|
M. Mares
SL-121
In vitro activity of a novel propiconazole derivative (MXP-4509)
nanoparticle-formulated
|
03:00
03:20
p.m.
|
K.W. Wellington
SL-122
A Laccase-catalysed synthesis of naphthoquinone
Bis-Sulfides
|
03:00
03:20
p.m.
|
L. Moezi
SL-123
The effect of pioglitazone, a specific ligand of the
proxisome prolifrator-activated receptor gamma, on ethanol - induced gastric
ulcers in cirrhotic rats: The role of nitric oxide and IL1-β
|
03:00
03:30
p.m.
|
W. Moos
IL-124
Nonprofit pharma
|
|
03:30
03:50
p.m.
|
A.Y. Ozer
SL-125
Investigating cold chain system and efficacy of vaccines
that have reached to the market in Turkey and related legal provisions
|
03:20
03:40
p.m.
|
A.K. Gajjar
SL-126
Impurity profiling: A case study of ezetimibe
|
03:20
03:40
p.m.
|
J. Tazi
SL-127
Therapeutic modulation of HIV-1 alternative splicing by
small molecules: A novel strategy for AIDS treatment
|
03:20
03:40
p.m.
|
B.H. Jacobson
SL-128
Efficacy of two concentrations of comfrey root (symphytum
officinale L.) extract ointments combined with tannic acid in the
treatment of patients with primary osteoarthritis of the knee: A
double-blind, randomized, multicenter, placebo-controlled trial
|
03:20
03:40
p.m.
|
J. Lipozencic
SL-129
Toxic epidermal necrolysis with fatal outcome by lansoprasole
|
03:30
03:50
p.m.
|
Assem S. el Baghdady
SL-130
Unlocking the market potential of academic research
|
|
03:50
04:10
p.m.
|
B. Stefanovic
SL-131
A novel target for antifibrotic drugs and a high
throughput assay to screen for such drugs
|
03:40
04:00
p.m.
|
M. Claybourn
SL-132
Technology and scientific advancements that will lead to
further improvements in understanding drug behavior
|
03:40
04:00
p.m.
|
C.O.Rangel-Yagui
SL-133
Micellar partition coefficient of drugs as a parameter
to estimate blood-brain barrier penetration
|
03:40
04:00
p.m.
|
K. Awang
SL-134
The Malaysian flora, a rich source of lead compounds
|
03:40
04:00
p.m.
|
J.G. Zayas
SL-135
Developing a new paradigm in respiratory hygiene to
control transmission of infectious respiratory diseases and to optimize
respiratory secretions management
|
03:50
04:10
p.m.
|
G. AlTajir
SL-136
Regulatory requirements in collaborative research
|
|
04:10
04:30
p.m.
|
B. Chen
SL-137
Ginkgolide B inhibition of the inflammatory protein
expression associated with reduce NOX4 expression and NF-κB activation in ox-LDL-stimulated
HUVECs
|
04:00
04:20
p.m.
|
H. Lamela
SL-138
New laser optoacoustic spectroscopy (LOS) system to
quantify gold nanoparticles in a liquid tissue phantom for biomedical
applications
|
04:00
04:20
p.m.
|
Zia-ur-Rehman
SL-139
Structural properties, antimicrobial and anticancer
potency of new organotin(IV) dithiocarboxylates
|
04:00
04:20
p.m.
|
F. Maiza-Benabdesselam
SL-140
Antibacterial activity of essential oils of two Algerian
medicinal plants orignum glandulosum Desf. And Artemisia herba alba Asso
|
04:00
04:20
p.m.
|
M.B. Jakovljevic
SL-141
Anticonvulsant plasma concentration impact on seizure
control, life quality and drug adverse events in teenagers and adult youths
with epilepsy
|
04:10
04:30
p.m
|
A.M. Al-Ghananeem
SL-142
Challenges in parenteral dosage from preparations of
slightly water-soluble drugs: dantrolene sodium’s successful example of
academic-industrial collaboration
|
|
04:30
04:50
p.m.
|
B. Azizi
SL-143
GFP chromophores as potential ligands for the estrogen
receptor and the pregnane X Receptor
|
04:20
04:50
p.m.
|
H. Durchschlag
IL-144
Prediction of discrete water molecules preferentially
bound to proteins and of water channels in protein interiors
|
04:20
04:40
p.m.
|
A. Badshah
SL-145
DNA binding potency of new ferrocenyl amides
|
04:20
04:40
p.m.
|
S.M. Adekenov
SL-146
Prospects of development of new preparations on the
basis of natural sesquiterpene lactones
|
04:20
04:50
p.m.
|
C.D. Ribas
IL-147
Long-Term effects of long-acting beta 2-agonists: What
the literature tells and doesn’t tell us
|
04:30
04:50
p.m
|
Yazeed A Al-Sheikh
SL-148
Assessing inborn errors of metabolism in Saudi Arabia
and improved methods of screening and diagnosis
|
|
POSTER PRESENTATION: 04:40 – 6:00 p.m.
|
|
Posters Session: 4:40 – 6:00 p.m. at corridor
Shopping Tour: Departure at 6:00 p.m.
|
|
DAY 4:
Thursday, February 10, 2011
|
|
PLENARY SESSION
|
|
Time
|
Chairman: W. Arber
Co-Chairman: D.K. Lahiri
|
Speaker
|
Title
|
|
09:00 09:45
a.m.
|
Location: Auditorium
|
T. Bocan
PL-149
|
Application of platform imaging biomarkers
in drug discovery - focus on neuroscience, oncology and cardiovascular
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
Hall No. HS-1008
(Ground Floor)
|
|
|
Diabetes & Obesity Drug Discovery & Therapy
|
Stereoselective Synthesis of Bioactive Compounds/ Enabling Technologies
|
Pharmaceutical Research & Development
|
Cardiovascular Drug Discovery & Therapy
|
Innovative Drug Discovery & Nanotechnology
|
Protein & Peptide Sciences
|
|
|
Chairman: R.J. Anto
Co-Chairman:
F. Vyskocil
|
Chairman: B.H. Jacobson
Co-Chairman: J.K. Ray
|
Chairman: M.A. O’Neil-Johnson
Co-Chairman: J. Tazi
|
Chairman: F. Huq
Co-Chairman: M.D. Hamalainen
|
Chairman: J.G. Zayas
Co-Chairman: R.L. Jones
|
Chairman: M.I. Choudhary
Co-Chairman: D.K. Lahiri
|
|
09:50
10:20
a.m.
|
S. V. Karnataki
IL-150
Diabetes and obesity drug discovery and therapy
|
09:50
10:20
a.m.
|
M.F.A. Adamo
IL-151
Novel synthetic methodologies to prepare unnatural acids, aminoacids
and peptidomimetics
|
09:50
10:20
a.m.
|
V.I. Perez-Nueno
IL-152
Predicting drug polypharmacology by correlating ligand
and target shape similarities
|
09:50
10:20
a.m.
|
S.D. Bergese
IL-153
Perioperative blood pressure control, is clevidipine the
answer?
|
09:50
10:20
a.m.
|
T. Moos
IL-154
Gene delivery by pullulan derivatives in brain capillary
endothelial cells for protein secretion
|
09:50
10:10
a.m.
|
T. Santos-Silva
SL-155
CORM-3 Reactivity towards proteins: The crystal
structure of a Ru(II) Dicarbonyl-Lysozyme complex
|
|
10:20
10:40
a.m.
|
C.-H. Chou
SL-156
Hypoglycemic natural products of cucurbitaceae-type
triterpenoids from plants of the cucurbitaceae family
|
10:20
10:40
a.m.
|
H.A. Al Attar
SL-157
Monitoring the emergence of drug resistance in patients
treated with imatinib (GlivecR) by identifying SNP in ABL portion of the
BCR-ABL oncogene using fluorescence method
|
10:20
10:40
a.m.
|
A. Alfaki
SL-158
Cardiac neurons firing precedes cortical neurons firing
by variable time equivalent to RP or Lipet’s latency period in goal directed
behavior or action in conscious state
|
10:20
10:40
a.m.
|
K. Smiljanic
SL-159
Involvement of MMP-2 and ADAM-12 in thrombin-induced
rat’ VSMCs proliferation
|
10:20
10:40
a.m.
|
M.V. Khvostov
SL-160
The improvement of toxico-pharmacological properties of
drugs by clathration with plant metabolities
|
10:10
10:30
a.m.
|
B. Kundu
SL-161
A novel thermostable L-asparaginase with a promising
anti-cancer activity
|
|
OFFEE BREAK: 10:40 – 11:10 a.m.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lecture Hall
(Ground Floor)
|
Multipurpose Hall
(Hall 1 - First Floor)
|
Hall No. 2
(First Floor)
|
Hall No. 3
(First Floor)
|
Hall No. 4
(First Floor)
|
Hall No. HS-1008
(Ground Floor)
|
|
|
Anti-Cancer Drug Discovery & Therapy/ Drug Delivery & Targeting
|
Regenerative Medicine/ Pulmonary Drug Discovery & Therapy
|
Diabetes and Obesity Drug Discovery & Therapy/
Cardiovascular Drug Discovery & Therapy/ Oncology
|
Recent Advances in Patient Treatment & Care
|
Biologics/In-Silico Drug Design & In-Silico Screening
|
Drug Discovery in Preclinical Research/Combinatorial Chemistry/ Innovative Drug Discovery & Nanotechnology/ Pharmaceutical Biotechnology
|
|
|
Chairman: V.I. Perez-Nueno
Co-Chairman: G. Shahnaz
|
Chairman: M.I. Choudhary
Co-Chairman: A. Kocak
|
Chairman: T. Moos
Co-Chairman: M.V. Khvostov
|
Chairman: R.H. Davies
Co-Chairman: A. Di Pietro
|
Chairman: M.F.A. Adamo
Co-Chairman: R. Pasqualini
|
Chairman: D. Li
Co-Chairman: M.-T. Liong
|
|
11:10
11:40
a.m.
|
F. Huq
IL-162
Synergism from combinations of platinums with
phytochemicals as applied to ovarian cancer
|
11:10
11:40
a.m.
|
A. Al-Hendy
IL-163
Adenovirus-mediated overexpression of human tissue
plasminogen activator prevents peritoneal adhesion formation/reformation
|
11:10
11:40
a.m.
|
K. Miyashita
IL-164
cGMP-dependent protein kinase cascades increase muscle
mitochondrial content and prevent obesity and diabetes
|
11:10
11:40
a.m.
|
M.R. El-Gewely
IL-165
CCMP, a new road for the treatment of monogenic diseases
due to mutations; its use on chemo-resistant cancers
|
11:10
11:40
a.m.
|
S. Dubel
IL-166
Human antibody – Human RNase fusion proteins for tumor
therapy
|
11:10
11:40
a.m.
|
J.N. Bryan
IL-167
Use of spontaneously arising canine lymphoma as a preclinical
model of DNA methylation derangements for drug target identification
|
|
11:40
12:10
p.m.
|
G. Birkenmeier
IL-168
How to command the wnt/B-cantenin pathway from outside
of the tumor cell: the A2M-LRP1 axis
|
11:40
12:00
noon
|
J.A. Andrades
SL-169
Articular cartilage regeneration by autologous
mesenchymal stem cells using a novel nano-composite collagenous scaffold
|
11:40
12:10
p.m.
|
K.C. Norris
IL-170
A novel cystine based antioxidant attenuates high fat
diet-induced oxidative stress and hepatic steatosis in apoliporotein E
knockout mice
|
11:40
12:10
p.m.
|
H. Chao
IL-171
L-DOS47 – A phase I/II lung cancer candidate that uses
tumor alkalization as a therapeutic approach
|
11:40
12:10
p.m.
|
M.F. Bachmann
IL-172
Targeting plasmocytoid dendritic cells with protein-based
nanoparticles for the treatment of asthma
|
11:40
12:10
p.m.
|
J. Spencer
IL-173
Parallel synthesis of libraries of medicinal interest
|
|
12:10
12:30
p.m.
|
J.M. Moshi
SL-174
The effects of UV solar light radiation on live cells
using yeast (Saccharomyces cerevisiae) as a model of eukaryotes
|
12:00
12:20
p.m.
|
L.M. Popescu
SL-175
Telocytes and stem cells: a tandem in cardiac
regenerative medicine
|
12:10
12:30
p.m.
|
M. Sharma
SL-176
Evaluation of antidiabetic and antioxidant effects of
Seabuckthorn (Hippophae rhamnoides L.) in streptozotocin-nicotinamide induced
type-2 diabetic rats
|
12:10
12:40
p.m.
|
V.D. Garovic
IL-177
Podocyturia in patients treated with VEGF blocking
therapy for cancer
|
12:10
12:30
p.m.
|
M.R. El-Gewely
SL-178
Early-stage hurdles in recombinant therapeutics development
and the impact of our novel Conformases/Foldases
|
12:10
12:30
p.m.
|
L. Saleh
SL-179
Selenopeptide phage display: Chemical modification and
applications
|
|
12:30
01:00
p.m.
|
I. Toth
IL-180
Multi-epitopic vaccine delivery system: Synthesis and
investigation
|
12:20
12:40
p.m.
|
SL-181
|
12:30
12:50
p.m.
|
P. Cervinka
SL-182
Optical coherence tomography guided primary PCI in STEMI
patients. A pilot study
|
12:40
01:00
p.m.
|
R. Turner
SL-183
Plasma coating – Meeting the Hfa challenge, the latest
in can Technology is here
|
12:30
01:00
p.m.
|
IL-184
|
12:30
01:00
p.m.
|
S.S. Farber
IL-185
A new approach to the design and synthesis of drugs
based on self-organizing quasi-life systems
|
|
01:00
01:20
p.m.
|
N.E. Polyakov
SL-186
Water soluble drugs conjugates with oligo- and
polysaccharides. New approach for drug design and delivery
|
12:40
01:00
p.m.
|
M.S. Kannan
SL-187
Role of CD38 in Asthma
|
12:50
01:10
p.m.
|
A. Kopylov
SL-188
Novel modular DNA aptamer for human thrombin with high
anticoagulant activity
|
01:00
01:20
p.m.
|
N. Arslani
SL-189
Advantages of new materials in fascia transversalis
reinforcement for inguinal hernia repair
|
01:00
01:20
p.m.
|
V. Ramakrishnan
SL-190
A ‘reductionist’ approach in virtual activity profiling
of drug molecules
|
01:00
01:20
p.m.
|
P. Srinivas
SL-191
Acyclovir loaded solid lipid nanoparticulate systems –
Formulation, characterization and pharmacokinetic evaluation for oral and
parenteral routes
|
|
01:20
01:40
p.m.
|
Anmin Li
SL-192
Magnetic paclitaxel nanoparticles inhibit glioma growth
and improve the survival of rats bearing glioma xenografts
|
01:00
01:20
p.m.
|
P.A. Singleton
SL-193
High molecular weight hyaluronan is a novel inhibitor of
acute lung injury
|
01:10
01:30
p.m.
|
S. Sirpal
SL-194
Injury, infection, and inflammation – The trilogy of
vascular disease
|
01:20
01:40
p.m.
|
M. Kabir-Salmani
SL-195
Properties of L-type amino acid transporter 1 (LAT1) in
epidermal ovarian cancer
|
01:20
01:40
p.m.
|
M. El-Hefnawi
SL-196
Computer-Aided drug design and drug discovery efforts
for hepatitis C virus: Novel polymerase inhibitors and optimal small
interfering RNAs targeting the HCV genome
|
01:20
01:40
p.m.
|
Z. Zakaria
SL-197
In-vitro production of antioxidants of naringin and hesperidin and
their activity in unsaturated fatty acid for oil preparation pharmaceuticals
|
|
01:40
02:00
p.m.
|
B. El-Gamal
SL-198
New trends in drug delivery and targeting: Potential
clinical applications
|
01:20
01:40
p.m.
|
S. Rao
SL-199
Levofloxacin in retreatment of Pulmonary Tuberculosis –
An experience with twenty patients
|
01:30
01:50
p.m.
|
A.B.M.F. Karim
SL-120
Chemotherapy induced thrombocytopenia for solid cancer
and lymphoma: A novel herbal solution
|
01:40
02:00
p.m.
|
C.D. Ribas
SL-201
Omalizumab effect in non-allergic asthma patients
|
01:40
02:00
p.m.
|
A. Nandy
SL-202
Multational patters in avian and swine flue viruses and
identification of surface exposed conserved region in neuraminidase and VP7
proteins by graphical representation and numerical characterization (granch)
studies
|
01:40
02:00
p.m.
|
A. Grammenos
SL-203
A combination of ESR and SANS techniques to explore the
Cyclodextrin action on membranes
|
|
01:40
02:00
p.m.
|
S.O. Arslan
SL-204
Evaluation by in vivo respiration enrolled of
lung toxicity in rats kept in coal mine ambience: effect of antioxidant
therapy
|
02:00
02:20
p.m.
|
H.G. Abdelhady
SL-205
4Dimensions atomic force microscopy investigation of the
packing and un-packing of dendritic-DNA nanoplexes
|
|
LUNCH BREAK: 02:00 – 03:15 p.m.
POSTER PRESENTATIONS: 03:15 – 4:15 p.m.
CASH PRIZE ANNOUNCEMENT FOR THREE BEST
POSTERS: 4:15 p.m.
POSTER PRESENTER’S PRESENCE IS ESSENTIAL
TO RECEIVE THE CASH AWARD AND CERTIFICATE OF MERIT
|
|
Posters Session: 03:15 – 4:15 p.m.
City Tour: Departure at 4:20 p.m.
IMPORTANT: The buses will leave daily from all Hotels at 8:15 a.m.
for the conference venue.
PL: Plenary Lecture
SIL: Special Invited Lecture
IL: Invited Lecture
SL: Session Lecture
|
